Tandem Diabetes Care Inc (NASDAQ:TNDM) EVP Brian B. Hansen sold 15,000 shares of Tandem Diabetes Care stock in a transaction on Monday, November 4th. The shares were sold at an average price of $62.01, for a total transaction of $930,150.00. Following the completion of the transaction, the executive vice president now owns 17,991 shares in the company, valued at approximately $1,115,621.91. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of NASDAQ:TNDM traded up $3.92 during midday trading on Thursday, hitting $61.12. 19,725 shares of the company’s stock traded hands, compared to its average volume of 1,045,430. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.21 and a current ratio of 2.53. The company has a market cap of $3.67 billion, a PE ratio of -23.80 and a beta of 0.16. The firm’s fifty day moving average price is $60.53 and its two-hundred day moving average price is $63.75. Tandem Diabetes Care Inc has a twelve month low of $26.40 and a twelve month high of $74.81.
Several large investors have recently bought and sold shares of TNDM. Nisa Investment Advisors LLC increased its position in shares of Tandem Diabetes Care by 53.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock worth $30,000 after purchasing an additional 160 shares during the last quarter. TRUE Private Wealth Advisors bought a new stake in shares of Tandem Diabetes Care during the 2nd quarter valued at about $33,000. First Quadrant L P CA bought a new stake in shares of Tandem Diabetes Care during the 3rd quarter valued at about $34,000. James Investment Research Inc. grew its position in shares of Tandem Diabetes Care by 15.9% during the 2nd quarter. James Investment Research Inc. now owns 1,315 shares of the medical device company’s stock valued at $85,000 after buying an additional 180 shares during the last quarter. Finally, Stephens Inc. AR bought a new stake in shares of Tandem Diabetes Care during the 2nd quarter valued at about $113,000. Institutional investors and hedge funds own 80.49% of the company’s stock.
A number of brokerages have weighed in on TNDM. ValuEngine upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating in a report on Friday, November 1st. BidaskClub lowered shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Oppenheimer lifted their target price on shares of Tandem Diabetes Care from $80.00 to $84.00 in a report on Friday, August 2nd. Robert W. Baird reduced their target price on shares of Tandem Diabetes Care from $81.00 to $71.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Guggenheim assumed coverage on shares of Tandem Diabetes Care in a report on Thursday, October 17th. They set a “buy” rating and a $76.00 target price on the stock. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Tandem Diabetes Care currently has an average rating of “Buy” and an average price target of $76.54.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Featured Story: Dividend Reinvestment Plan (DRIP)
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.